Epkinly shows 51% lower risk of progression in frontline DLBCL trial, boosting hopes for expanded approval

New Phase 3 data from the Epkinly and R-CHOP combination in diffuse large B cell lymphoma showed a 51% reduction in the risk of disease progression or death compared with standard therapy. The study evaluated Epkinly as a frontline treatment for patients who have not received prior therapy.

Analysts described the results as highly differentiated and suggested the regimen could become a new standard of care, noting its performance compares favorably with existing options such as Roche’s Polivy and Incyte’s Monjuvi.

During the same week, the sector saw several notable deals, including Novartis’ announcement of an almost $8 billion partnership with China’s Abogen Biosciences to develop mRNA medicines. IntraBio also agreed to a $2 billion buyout by a Japanese firm.

The report also mentioned that Sarepta Therapeutics is seeking to reverse a difficult previous year, though specific strategies were not detailed.